72 related articles for article (PubMed ID: 6717895)
1. Pharmacokinetics of Lonidamine after oral administration in cancer patients.
Besner JG; Leclaire R; Band PR; Deschamps M; De Sanctis AJ; Catanese B
Oncology; 1984; 41 Suppl 1():48-52. PubMed ID: 6717895
[TBL] [Abstract][Full Text] [Related]
2. Oral absorption of bendazac lysine salt in man after repeated administrations.
Barillari G; Iorio E; Galli Angeli D; Catanese B
Pharmacol Res Commun; 1983 May; 15(5):461-71. PubMed ID: 6889423
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of lonidamine.
Segre G; Catanese B
Chemotherapy; 1981; 27 Suppl 2():77-84. PubMed ID: 7285639
[No Abstract] [Full Text] [Related]
5. Early observations on the administration of Lonidamine in cancer patients.
Barduagni A; Barduagni M; Di Lauro L; Nardi M; Gallo Curcio C; Tonachella R; Ciottoli GB; Delle Chiaie S
Oncology; 1984; 41 Suppl 1():78-81. PubMed ID: 6717900
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery.
Harpsøe NG; Andersen LP; Mielke LV; Jønsson B; Jenstrup MT; Gögenur I; Rosenberg J
Clin Drug Investig; 2016 Dec; 36(12):1045-1050. PubMed ID: 27566320
[TBL] [Abstract][Full Text] [Related]
7. [Absorption, metabolism and excretion of 2-methyl-3-methylamino-4,5,6,7-tetrahydroindazole (tetridamine) in the rat].
Massaroli G; Cellari C; Coerezza M; Scuri R
Boll Chim Farm; 1972 Nov; 111(11):649-57. PubMed ID: 4655669
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Cancer Chemother Pharmacol; 1996; 38(2):129-35. PubMed ID: 8616902
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling.
Besner JG; Leclaire R; Roy JJ
Drug Metab Rev; 1997; 29(1-2):219-34. PubMed ID: 9187520
[No Abstract] [Full Text] [Related]
10. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Kharasch ED; Hoffer C; Walker A; Sheffels P
Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the oral absorption in man of bendazac and its lysine salt.
Catanese B; Barillari G; Iorio E; Silvestrini B
Boll Chim Farm; 1982 Feb; 121(2):87-90. PubMed ID: 7126348
[No Abstract] [Full Text] [Related]
12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
13. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis.
Rovei V; Escourrou J; Campistron G; Ego D; Thiola A; Ribet A; Houin G
Eur J Clin Pharmacol; 1988; 35(4):391-6. PubMed ID: 3197747
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
Kanaze FI; Bounartzi MI; Georgarakis M; Niopas I
Eur J Clin Nutr; 2007 Apr; 61(4):472-7. PubMed ID: 17047689
[TBL] [Abstract][Full Text] [Related]
16. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of benzydamine.
Chasseaud LF; Catanese B
Int J Tissue React; 1985; 7(3):195-204. PubMed ID: 4044147
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
Cox DS; Papadopoulos K; Fang L; Bauman J; LoRusso P; Tolcher A; Patnaik A; Pendry C; Orford K; Ouellet D
J Clin Pharmacol; 2013 Sep; 53(9):946-54. PubMed ID: 23893461
[TBL] [Abstract][Full Text] [Related]
19. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects.
Rittig S; Jensen AR; Jensen KT; Pedersen EB
Clin Endocrinol (Oxf); 1998 Feb; 48(2):235-41. PubMed ID: 9579238
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
